Q1 Earnings Forecast for CTXR Issued By HC Wainwright

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Citius Pharmaceuticals in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Citius Pharmaceuticals' current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals' Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2026 earnings at $0.05 EPS.

Citius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01).

Citius Pharmaceuticals Trading Down 20.0 %

Shares of CTXR traded down $0.10 during trading hours on Wednesday, hitting $0.39. 2,412,377 shares of the stock were exchanged, compared to its average volume of 1,440,665. The business has a 50-day moving average of $0.44 and a 200-day moving average of $0.61. Citius Pharmaceuticals has a fifty-two week low of $0.31 and a fifty-two week high of $1.07.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the 2nd quarter valued at about $29,000. BNP Paribas Financial Markets raised its position in shares of Citius Pharmaceuticals by 88.5% during the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company's stock worth $62,000 after purchasing an additional 32,686 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth $69,000. Arkadios Wealth Advisors lifted its holdings in shares of Citius Pharmaceuticals by 50.0% in the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company's stock worth $88,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Wealth Advisory Solutions LLC grew its position in Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company's stock valued at $101,000 after purchasing an additional 50,000 shares during the period. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.